{"status":"OK","data":{"id":2723728,"identifier":"DVN/NBLACA","persistentUrl":"https://doi.org/10.7910/DVN/NBLACA","protocol":"doi","authority":"10.7910","publisher":"Harvard Dataverse","publicationDate":"2016-03-10","storageIdentifier":"s3://dvn-cloud:10.7910/DVN/NBLACA","latestVersion":{"id":77861,"storageIdentifier":"s3://dvn-cloud:10.7910/DVN/NBLACA","versionNumber":1,"versionMinorNumber":0,"versionState":"RELEASED","productionDate":"Production Date","lastUpdateTime":"2016-03-10T09:17:09Z","releaseTime":"2016-03-10T09:17:09Z","createTime":"2015-11-10T10:13:46Z","license":"CC0","termsOfUse":"CC0 Waiver","metadataBlocks":{"citation":{"displayName":"Citation Metadata","fields":[{"typeName":"title","multiple":false,"typeClass":"primitive","value":"Labcode 6B- HIV neutralization Protocol PBMC based HIV-1 Neutralization Assay"},{"typeName":"author","multiple":true,"typeClass":"compound","value":[{"authorName":{"typeName":"authorName","multiple":false,"typeClass":"primitive","value":"Betty Willems;"},"authorAffiliation":{"typeName":"authorAffiliation","multiple":false,"typeClass":"primitive","value":"Institute of Tropical Medicine, Belgium"}}]},{"typeName":"datasetContact","multiple":true,"typeClass":"compound","value":[{"datasetContactName":{"typeName":"datasetContactName","multiple":false,"typeClass":"primitive","value":"Betty Willems;"},"datasetContactAffiliation":{"typeName":"datasetContactAffiliation","multiple":false,"typeClass":"primitive","value":"Institute of Tropical Medicine, Belgium"},"datasetContactEmail":{"typeName":"datasetContactEmail","multiple":false,"typeClass":"primitive","value":"bwillems@itg.be"}}]},{"typeName":"dsDescription","multiple":true,"typeClass":"compound","value":[{"dsDescriptionValue":{"typeName":"dsDescriptionValue","multiple":false,"typeClass":"primitive","value":"This document contains a detailed protocol on detection of neutralizing activity of monoclonal antibodies (mAb) as well as sera/plasma obtained from HIV infected individuals using a PBMC assay. In this assay an extended (24 hr) incubation period of virus and neutralizing agent prior adding the PHA/IL-2 stimulated PBMC is used. Antibody is assessed by measuring the p24 in the culture supernatant using an ‘in-house’ quantitative ELISA."}}]},{"typeName":"subject","multiple":true,"typeClass":"controlledVocabulary","value":["Medicine, Health and Life Sciences"]},{"typeName":"depositor","multiple":false,"typeClass":"primitive","value":"sheik-khalil, enas"},{"typeName":"dateOfDeposit","multiple":false,"typeClass":"primitive","value":"2015-11-10"}]}},"files":[{"label":"Labcode 6B- HIV neutralization Protocol PBMC based HIV-1 Neutralization Assay.pdf","restricted":false,"version":1,"datasetVersionId":77861,"dataFile":{"id":2723729,"persistentId":"doi:10.7910/DVN/NBLACA/ZUSVHB","pidURL":"https://doi.org/10.7910/DVN/NBLACA/ZUSVHB","filename":"Labcode 6B- HIV neutralization Protocol PBMC based HIV-1 Neutralization Assay.pdf","contentType":"application/pdf","filesize":255274,"storageIdentifier":"s3://dvn-cloud:150f0e30c30-b986a92efb18","rootDataFileId":-1,"md5":"04b017d871475c2fadf7abdb2a4ad081","checksum":{"type":"MD5","value":"04b017d871475c2fadf7abdb2a4ad081"}}}]}}}